Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC

Genentech, a member of the Roche Group, is set to present new data from its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference® 2026 in London on July 12-15. These findings showcase the companies’ ongoing commitment to developing next-generation treatments and diagnostic tests aimed at slowing or stopping the progression of Alzheimer’s disease.

Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Biogen will present new findings at the Alzheimer’s Association International Conference (AAIC) 2026, set for July 12–15 in London. This includes data from the Phase 2 CELIA study of diranersen, an investigational tau-targeting ASO, as well as additional analyses of LEQEMBI (lecanemab).

Ronald Phelps

Ronald Joseph “Ronnie” Phelps, 94, of La Crosse, Wisconsin, passed away peacefully on January 9, 2026, at the Tomah VA Medical Center. His final days were marked by resilience and strength, following a courageous battle with Alzheimer’s disease.

Ronald Phelps